| 王雅静,徐竟益,刘影,任志忠,王天霄,汪桠琴,张跃伟.FOLFOX-肝动脉灌注化疗联合靶向及免疫治疗巴塞罗那临床肝癌C期肝细胞癌[J].中国介入影像与治疗学,2022,19(11):687-692 |
| FOLFOX-肝动脉灌注化疗联合靶向及免疫治疗巴塞罗那临床肝癌C期肝细胞癌 |
| FOLFOX hepatic artery infusion chemotherapy combined with targeted therapy and immunotherapy for Barcelona clinic liver cancer stage C hepatocellular carcinoma |
| 投稿时间：2022-05-20 修订日期：2022-07-11 |
| DOI：10.13929/j.issn.1672-8475.2022.11.004 |
| 中文关键词: 肝脏肿瘤 肝动脉 化学治疗,肿瘤,局部灌注 分子靶向治疗 免疫治疗 |
| 英文关键词:liver neoplasms hepatic artery chemotherapy,cancer,regional perfusion molecular targeted therapy immunotherapy |
| 基金项目: |
| 作者 | 单位 | E-mail | | 王雅静 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | | | 徐竟益 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | | | 刘影 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | | | 任志忠 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | | | 王天霄 | 清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218
山东大学齐鲁医学院第二医院肝胆外科, 山东 济南 250033 | | | 汪桠琴 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | | | 张跃伟 | 清华大学临床医学院, 北京 100084
清华大学附属北京清华长庚医院肝胆胰中心, 北京 102218 | zhangyuewei1121@sina.com |
|
| 摘要点击次数: 753 |
| 全文下载次数: 209 |
| 中文摘要: |
| 目的 观察以FOLFOX方案为核心的肝动脉灌注化疗(HAIC)联合靶向及免疫治疗巴塞罗那临床肝癌(BCLC)-C期肝细胞癌(HCC)的效果和安全性。方法 回顾性分析21例接受HAIC联合靶向及免疫治疗的BCLC-C期HCC患者,记录患者总生存期(OS)及无进展生存期(PFS),计算总缓解率(ORR)和疾病控制率(DCR),以及治疗及随访期间不良事件。结果 治疗后ORR、DCR分别为57.14%(12/21)和95.24%(20/21)。随访4~33个月、中位时间15个月,期间13例死于肿瘤进展;中位OS为11.0[95%CI(6.47,15.52)]个月,中位PFS为5.0[95%CI(4.23,5.76)]个月。不良事件中,1~2级较为常见;治疗期间16例出现3级不良事件,其中1例死于免疫相关性肺炎,15例均于下一治疗周期前恢复。结论 FOLFOX-HAIC联合靶向及免疫治疗BCLC-C期HCC安全、有效。 |
| 英文摘要: |
| Objective To observe the efficacy and safety of FOLFOX regimen based hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy for Barcelona clinic liver cancer (BCLC) C stage hepatocellular carcinoma (HCC). Methods Data of 21 BCLC-C HCC patients who underwent HAIC combined with targeted therapy and immunotherapy were retrospectively analyzed. The overall survival (OS) and progression-free survival (PFS) were recorded, and the overall response rate (ORR) and disease control rate (DCR) were calculated. Adverse events occurred during treatment and follow-up periods were recorded. Results ORR and DCR after treatment was 57.14% (12/21) and 95.24% (20/21), respectively. The total follow-up time was 4 to 33 months, with the median time of 15 months, and 13 cases died due to progression. The median OS was 11.0 (95%CI [6.47, 15.52]) months, and the median PFS was 5.0 (95%CI [4.23, 5.76]) months. Adverse events of grade 1 to 2 were common, while 16 cases experienced grade 3 adverse events during treatments, including 1 patient died of immune-associated pneumonia and the other 15 recovered before the next treatment cycle. Conclusion FOXFOL-HAIC combined with targeted therapy and immunotherapy was safe and effective for treating BCLC-C HCC. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
